Napredna pretraga

Pregled bibliografske jedinice broj: 547074

Focus on Ulcerative Colitis : Stable Gastric Pentadecapeptide BPC 157


Sikirić, Predrag; Seiwerth, Sven; Ručman, Rudolf; Turković, Branko; Stančić-Rokotov, Dinko; Brčić, Luka; Sever, Marko; Kliček, Robert; Radić, Božo; Drmić, Domagoj et al.
Focus on Ulcerative Colitis : Stable Gastric Pentadecapeptide BPC 157 // Current medicinal chemistry, 19 (2012), 1; 126-132 doi:10.2174/092986712803414015 (međunarodna recenzija, pregledni rad, znanstveni)


Naslov
Focus on Ulcerative Colitis : Stable Gastric Pentadecapeptide BPC 157

Autori
Sikirić, Predrag ; Seiwerth, Sven ; Ručman, Rudolf ; Turković, Branko ; Stančić-Rokotov, Dinko ; Brčić, Luka ; Sever, Marko ; Kliček, Robert ; Radić, Božo ; Drmić, Domagoj ; Ilić, Spomenko ; Kolenc, Danijela ; Stambolija, Vasilije ; Zoričić, Zoran ; Vrčić, Hrvoje ; Šebečić, Božidar

Izvornik
Current medicinal chemistry (0929-8673) 19 (2012), 1; 126-132

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
BPC 157; intestinal anastomosis; short bowel; colocutaneous fistulas; inflammatory bowel disease

Sažetak
Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-system, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve growth factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157’s high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Projekt / tema
108-1080321-0389 - Utjecaj pentadekapeptida BPC 157 na ženski urogenitalni sustav (Hrvoje Vrčić, )
108-1083570-3611 - Pentadekapeptid BPC 157- učinkovita terapija ozljeda mišića i tetive (Božidar Šebečić, )
108-1083570-3634 - Genetička istraživanja učinka BPC-157 na mikroorganizmima (Senka Džidić, )
108-1083570-3635 - Pentadekapeptid BPC 157 - daljnja istraživanja (Predrag Sikirić, )
108-1083570-3643 - Kvantitativna analiza i prijenos slike u patologiji (Sven Seiwerth, )

Ustanove
Medicinski fakultet, Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka:


  • MEDLINE


Citati